|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FEM1B |
Gene summary for FEM1B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FEM1B | Gene ID | 10116 |
| Gene name | fem-1 homolog B | |
| Gene Alias | F1A-ALPHA | |
| Cytomap | 15q23 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9UK73 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10116 | FEM1B | LZE4T | Human | Esophagus | ESCC | 1.02e-04 | 3.26e-01 | 0.0811 |
| 10116 | FEM1B | LZE7T | Human | Esophagus | ESCC | 2.74e-06 | 1.54e-01 | 0.0667 |
| 10116 | FEM1B | LZE8T | Human | Esophagus | ESCC | 3.79e-03 | -4.09e-02 | 0.067 |
| 10116 | FEM1B | LZE24T | Human | Esophagus | ESCC | 1.49e-13 | 1.52e-01 | 0.0596 |
| 10116 | FEM1B | LZE21T | Human | Esophagus | ESCC | 6.82e-09 | 1.69e-01 | 0.0655 |
| 10116 | FEM1B | LZE6T | Human | Esophagus | ESCC | 7.51e-03 | 7.36e-03 | 0.0845 |
| 10116 | FEM1B | P1T-E | Human | Esophagus | ESCC | 9.78e-10 | 2.98e-01 | 0.0875 |
| 10116 | FEM1B | P2T-E | Human | Esophagus | ESCC | 1.98e-23 | 4.72e-01 | 0.1177 |
| 10116 | FEM1B | P4T-E | Human | Esophagus | ESCC | 2.81e-15 | 4.08e-01 | 0.1323 |
| 10116 | FEM1B | P5T-E | Human | Esophagus | ESCC | 1.29e-09 | 2.75e-01 | 0.1327 |
| 10116 | FEM1B | P8T-E | Human | Esophagus | ESCC | 5.31e-22 | 2.41e-01 | 0.0889 |
| 10116 | FEM1B | P9T-E | Human | Esophagus | ESCC | 9.72e-13 | 3.91e-01 | 0.1131 |
| 10116 | FEM1B | P10T-E | Human | Esophagus | ESCC | 9.57e-25 | 4.08e-01 | 0.116 |
| 10116 | FEM1B | P11T-E | Human | Esophagus | ESCC | 3.04e-06 | 2.69e-01 | 0.1426 |
| 10116 | FEM1B | P12T-E | Human | Esophagus | ESCC | 2.43e-24 | 4.34e-01 | 0.1122 |
| 10116 | FEM1B | P15T-E | Human | Esophagus | ESCC | 4.30e-23 | 5.82e-01 | 0.1149 |
| 10116 | FEM1B | P16T-E | Human | Esophagus | ESCC | 3.16e-21 | 4.49e-01 | 0.1153 |
| 10116 | FEM1B | P20T-E | Human | Esophagus | ESCC | 1.06e-07 | 8.26e-02 | 0.1124 |
| 10116 | FEM1B | P21T-E | Human | Esophagus | ESCC | 7.92e-16 | 1.31e-01 | 0.1617 |
| 10116 | FEM1B | P22T-E | Human | Esophagus | ESCC | 5.36e-15 | 1.82e-01 | 0.1236 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
| GO:2001233111 | Esophagus | ESCC | regulation of apoptotic signaling pathway | 256/8552 | 356/18723 | 4.11e-24 | 1.04e-21 | 256 |
| GO:0097191111 | Esophagus | ESCC | extrinsic apoptotic signaling pathway | 159/8552 | 219/18723 | 4.12e-16 | 2.94e-14 | 159 |
| GO:2001236111 | Esophagus | ESCC | regulation of extrinsic apoptotic signaling pathway | 111/8552 | 151/18723 | 2.97e-12 | 1.18e-10 | 111 |
| GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
| GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
| GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
| GO:00000754 | Esophagus | ESCC | cell cycle checkpoint | 117/8552 | 169/18723 | 4.47e-10 | 1.17e-08 | 117 |
| GO:2001020110 | Esophagus | ESCC | regulation of response to DNA damage stimulus | 145/8552 | 219/18723 | 5.97e-10 | 1.50e-08 | 145 |
| GO:004277014 | Esophagus | ESCC | signal transduction in response to DNA damage | 117/8552 | 172/18723 | 2.38e-09 | 5.32e-08 | 117 |
| GO:0061458110 | Esophagus | ESCC | reproductive system development | 247/8552 | 427/18723 | 2.24e-07 | 3.42e-06 | 247 |
| GO:004860818 | Esophagus | ESCC | reproductive structure development | 245/8552 | 424/18723 | 2.82e-07 | 4.14e-06 | 245 |
| GO:00109484 | Esophagus | ESCC | negative regulation of cell cycle process | 177/8552 | 294/18723 | 3.26e-07 | 4.59e-06 | 177 |
| GO:00315705 | Esophagus | ESCC | DNA integrity checkpoint | 83/8552 | 123/18723 | 8.17e-07 | 1.06e-05 | 83 |
| GO:000206420 | Esophagus | ESCC | epithelial cell development | 136/8552 | 220/18723 | 9.50e-07 | 1.21e-05 | 136 |
| GO:000862519 | Esophagus | ESCC | extrinsic apoptotic signaling pathway via death domain receptors | 59/8552 | 82/18723 | 1.23e-06 | 1.52e-05 | 59 |
| GO:00000775 | Esophagus | ESCC | DNA damage checkpoint | 78/8552 | 115/18723 | 1.27e-06 | 1.56e-05 | 78 |
| GO:19019883 | Esophagus | ESCC | negative regulation of cell cycle phase transition | 151/8552 | 249/18723 | 1.28e-06 | 1.57e-05 | 151 |
| GO:002261216 | Esophagus | ESCC | gland morphogenesis | 78/8552 | 118/18723 | 5.83e-06 | 6.03e-05 | 78 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FEM1B | SNV | Missense_Mutation | c.653N>T | p.His218Leu | p.H218L | Q9UK73 | protein_coding | tolerated(0.67) | benign(0.023) | TCGA-BH-A0HB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
| FEM1B | insertion | Nonsense_Mutation | novel | c.1309_1310insACATCCCTTAAACATATGTTAGGCTGTGGCCTCTGTTATCTAACTGC | p.Met437AsnfsTer4 | p.M437Nfs*4 | Q9UK73 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| FEM1B | SNV | Missense_Mutation | novel | c.703N>A | p.Val235Ile | p.V235I | Q9UK73 | protein_coding | deleterious(0.01) | possibly_damaging(0.688) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FEM1B | SNV | Missense_Mutation | rs777760220 | c.1444N>T | p.Arg482Cys | p.R482C | Q9UK73 | protein_coding | deleterious(0) | possibly_damaging(0.828) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| FEM1B | SNV | Missense_Mutation | novel | c.1092C>G | p.Ile364Met | p.I364M | Q9UK73 | protein_coding | tolerated(0.15) | possibly_damaging(0.494) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| FEM1B | SNV | Missense_Mutation | rs775266107 | c.1381N>A | p.Glu461Lys | p.E461K | Q9UK73 | protein_coding | tolerated(0.49) | benign(0.134) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FEM1B | SNV | Missense_Mutation | c.599N>G | p.Ile200Arg | p.I200R | Q9UK73 | protein_coding | deleterious(0.01) | benign(0.009) | TCGA-IR-A3LB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| FEM1B | SNV | Missense_Mutation | c.365C>T | p.Ser122Leu | p.S122L | Q9UK73 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| FEM1B | SNV | Missense_Mutation | c.1439G>A | p.Arg480Lys | p.R480K | Q9UK73 | protein_coding | tolerated(0.31) | benign(0.132) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| FEM1B | SNV | Missense_Mutation | c.679N>A | p.Ala227Thr | p.A227T | Q9UK73 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AA-3712-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |